Why the study?
Does low-dose combination of ramipril and candesartan reduce proteinuria and urinary TGF-beta1 in type 2 diabetic patients with advanced kidney disease?
Population
21 type 2 diabetic patients with overt nephropathy, mean age 49 +/- 8 years, 11 male and 10 female.
Comparison
Low-dose combination therapy of ramipril plus… vs Ramipril alone and candesartan alone for 16…
Design
RCT, randomized crossover, double-blinded
Follow-up
Three 16-week treatment periods
Authors
Loading...
Supports low-dose dual RAS blockade over monotherapy for proteinuria reduction in advanced diabetic CKD; extends evidence to this population.
Does low-dose combination of ramipril and candesartan reduce proteinuria and urinary TGF-beta1 in type 2 diabetic patients with advanced kidney disease?
Low-dose dual blockade of the renin-angiotensin system with ramipril and candesartan offers additive benefits in reducing proteinuria and urinary TGF-beta1 excretion in type 2 diabetic patients with advanced kidney disease compared to higher-dose monotherapy.
Song et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: